Cannabinoid Signalling Group

The Cannabinoid Signalling Group belongs to the Department of Biochemistry and Molecular Biology at the Schools of Chemistry and Biology of the Complutense University of Madrid, and it is coordinated by Manuel Guzmán. Nowadays, Ismael Galve-Roperh, Cristina Sánchez and Guillermo Velasco lead three of the ongoing research lines in our group.

Cannabinoid Signalling Group

 The major focus of our group is the study of the mechanisms by which cannabinoids – the active components of Cannabis sativa L. – and their endogenous counterparts control the proliferation, differentiation and survival of different types of cells.

These are our research lines:

Recent publications

i

Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer (2019)

Blasco-Benito, S. et al.

Link to the article

For more publications from Breast Cancer, click here.

i

Δ9-Tetrahydrocannabinol promotes functional remyelination in the mouse brain (2021)

Aguado, T., Huerga-Gómez, A. et al.

Link to the article

Para ver más publicaciones del grupo de Neurogénesis, haz click aquí.

i

Identification of BiP as a CB 1 receptor-interacting protein that fine-tunes cannabinoid signaling in the mouse brain (2021)

 Costas-Insua, C. et al.

Link to the article

For more publications from Neuroprotection, click here.

i

The Pseudokinase TRIB3 Negatively Regulates the HER2 Receptor Pathway and Is a Biomarker of Good Prognosis in Luminal Breast Cancer (2021)

Orea-Soufi, A. et al.

Link to the article

For more publications from Brain Tumors, click here.

Acknowledgements

Our group acknowledges the support of funding institutions, both public and private.